One-year treatment cost of rubicatin/rubitidine and price after medical insurance reimbursement

Lurbinectedin , trade name ZEPZELCA (ZEPZELCA), is a targeted drug mainly used to treat metastatic small cell lung cancer (SCLC) . This drug interferes with the DNA synthesis of cancer cells through alkylation, thereby inhibiting the proliferation of cancer cells. It has been proven to prolong the survival of patients to a certain extent, especially for some patients with metastatic small cell lung cancer who are ineffective with traditional treatments. Although the clinical effect of rubitin has been recognized to a certain extent, because it is a new targeted drug, its treatment cost is relatively high, especially when there is no medical insurance reimbursement.

In China, the original drug (trade name ZEPZELCA) for the injectable drug Lurbinectedin (Lurbinectedin) has been approved and put on the market, but it has not yet been included in the scope of medical insurance reimbursement. According to current market information, each box of 4 mg Rubitidine is priced at approximately RMB 20,000. However, because the pricing of drugs is affected by factors such as market demand, supply, exchange rate fluctuations, etc., prices may change. For patients who require long-term treatment, the treatment cost of a single drug may reach 100,000 yuan or more in a year.

With the promotion and use of rupitidine in the Chinese market, if it can be included in the scope of medical insurance in the future, the treatment burden on patients will be greatly reduced. Judging from the situation of other targeted drugs, once included in medical insurance, the actual cost of the drug may be significantly reduced.

In the absence of medical insurance coverage, the high cost of rubitidine treatment may become an important factor that patients need to consider when choosing a treatment plan. In the future, with the update of medical insurance policies and the improvement of the drug market, the price of rubitidine may gradually adjust, allowing more patients to benefit from this innovative drug.

Reference materials:https://www.zepzelca.com/